The efficacy of flaxseed and hesperidin in non-alcoholic fatty liver disease


  • Dawn O'Shea
  • Univadis Medical News
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Hesperidin and flaxseed supplementation improved glucose and lipid metabolism, and reduce inflammation and hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD), reports a study in the European Journal of Clinical Nutrition.

While NAFLD is growing in prevalence globally, there is no definitive evidence for any approved pharmacological approaches. This study aimed to assess the clinical effects of flaxseed and hesperidin in patients with NAFLD.

In this randomised, controlled, clinical trial, 100 patients were assigned to four dietary intervention groups including lifestyle modification (control), lifestyle modification with 30 g whole flaxseed powder, lifestyle modification with 1 g hesperidin supplementation, and lifestyle modification with a combination of 30 g flaxseed and 1 g hesperidin (flax-hes).

After 12 weeks, significant reductions were seen in body mass index, glucose haemostasis parameters and hepatic steatosis. There was a significant effect for time relative to almost all paraclinical parameters.

The three intervention groups experienced significant decreases in plasma alanine aminotransferase levels, indices of insulin resistance and insulin sensitivity, fasting glucose and fatty liver index compared to controls (P<.008>

The authors say the study confirms that hesperidin and flaxseed supplementation improves glucose and lipid metabolism, while reducing inflammation and hepatic steatosis in patients with NAFLD.